Value in the bio-economy is managed through asset governance, not product sales.
Evidence
As this quote illustrates, understanding and judging value are not static or onetime events; they involve the continuous management of value, especially through the management and governance of the assets that constitute organizational entities (e.g., biotech firms). This is because, as Mirowski (2012) points out, most biotech firms have not—and will likely never— produce a product for sale. In this sense, STS scholarship on value in the bio-economy needs to start to incorporate assets into the mix, as some scholars have started to do already (e.g., Birch and Tyfield 2013; Cooper and Waldby 2014; Lezaun and Montgomery 2015; Martin 2015). — Kean Birch, Rethinking Value in the Bio-economy, 88
Categorization
- ADDENDUM: Directly extends the assetization thread from the financial reading purpose — connects to how firms without products still hold value through asset portfolios.
- XREF: connects to: Understanding value requires studying the assets underpinning firm valuation, not commodity production. — Kean Birch, Rethinking Value in the Bio-economy:…, 39; Asset value is constituted by active management within organizations, not by biological properties. — Kean Birch, Rethinking Value in the Bio-economy:…, 47; Biotech firms can be valued as strategic acquisitions, not for their revenue — Kean Birch, Rethinking Value in the Bio-economy:…, 76 (+4 more)
Related
- Understanding value requires studying the assets underpinning firm valuation, not commodity production. (similarity 0.94)
- Value in the bio-economy is better theorized through assetization than commodification. (similarity 0.92)
- Analyzing bio-economy value requires focusing on assets rather than commodities (similarity 0.92)
- In the bioeconomy, informational signaling about assets, not product sales, constitutes firm value. (similarity 0.91)
- Asset value is constituted by active management within organizations, not by biological properties. (similarity 0.90)
- Bio-economy valuation practices are not peculiar to that sector. (similarity 0.89)
- Life sciences firms may never produce products, so valuation is prospective rather than embodied (similarity 0.87)
- Value in the bio-economy is produced through valuation practices, not intrinsic to biological matter. (similarity 0.86)
- Biotech firms can be valued as strategic acquisitions, not for their revenue (similarity 0.85)
- Accounting for biological assets reflects chosen methods, not intrinsic biological qualities (similarity 0.85)
- Value is constituted by knowledge and practice, not merely hype. (similarity 0.85)
- Value is not inherent in things but achieved through capitalization practices. (similarity 0.84)
- Asset value derives from future earnings rather than intrinsic commodity value (similarity 0.84)
- Asset value is actively managed, including downward, and its constructedness is obscured. (similarity 0.83)
- Capitalization builds the thing being valued at the same time it appraises that thing (similarity 0.82)
Broader Connections
- In the bioeconomy, informational signaling about assets, not product sales, constitutes firm value.
#corroborates(0.92) — Kean Birch, Rethinking Value in the Bio-economy, 106 - Value in the bio-economy is better theorized through assetization than commodification.
#qualifies(0.80) — Kean Birch, Rethinking Value in the Bio-economy, 112 - Analyzing bio-economy value requires focusing on assets rather than commodities
#corroborates(0.78) — Kean Birch, Rethinking Value in the Bio-economy, 68 - Value emerges from relational valuation practices, not from objects themselves.
#expands(0.75) — Ève Chiapello, Financialisation of Valuation, 23